<?xml version='1.0' encoding='utf-8'?>
<document id="28403576"><sentence text="No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers."><entity charOffset="49-58" id="DDI-PubMed.28403576.s1.e0" text="Prasugrel" /><entity charOffset="63-72" id="DDI-PubMed.28403576.s1.e1" text="Vorapaxar" /><pair ddi="false" e1="DDI-PubMed.28403576.s1.e0" e2="DDI-PubMed.28403576.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28403576.s1.e0" e2="DDI-PubMed.28403576.s1.e1" /></sentence><sentence text="Vorapaxar is a first-in-class antagonist of the protease-activated receptor-1, the primary thrombin receptor on human platelets, which mediates the downstream effects of thrombin in hemostasis and thrombosis"><entity charOffset="0-9" id="DDI-PubMed.28403576.s2.e0" text="Vorapaxar" /></sentence><sentence text=" Prasugrel is a platelet inhibitor that acts as a P2Y12 receptor antagonist through an active metabolite, R-138727"><entity charOffset="1-10" id="DDI-PubMed.28403576.s3.e0" text="Prasugrel" /></sentence><sentence text=" This study investigated the interaction of these 2 platelet antagonists when coadministered" /><sentence text=" This was a randomized, open-label, multiple-dose study in 54 healthy volunteers consisting of a fixed-sequence crossover and a parallel group design" /><sentence text=" In sequence 1, 36 subjects received prasugrel 60 mg on day 1 and then prasugrel 10 mg once daily on days 2 to 7, followed by vorapaxar 40 mg and prasugrel 10 mg on day 8 and then vorapaxar 2"><entity charOffset="37-46" id="DDI-PubMed.28403576.s6.e0" text="prasugrel" /><entity charOffset="71-80" id="DDI-PubMed.28403576.s6.e1" text="prasugrel" /><entity charOffset="126-135" id="DDI-PubMed.28403576.s6.e2" text="vorapaxar" /><entity charOffset="146-155" id="DDI-PubMed.28403576.s6.e3" text="prasugrel" /><entity charOffset="180-189" id="DDI-PubMed.28403576.s6.e4" text="vorapaxar" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e0" e2="DDI-PubMed.28403576.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e0" e2="DDI-PubMed.28403576.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e0" e2="DDI-PubMed.28403576.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e0" e2="DDI-PubMed.28403576.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e0" e2="DDI-PubMed.28403576.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e1" e2="DDI-PubMed.28403576.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e1" e2="DDI-PubMed.28403576.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e1" e2="DDI-PubMed.28403576.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e1" e2="DDI-PubMed.28403576.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e2" e2="DDI-PubMed.28403576.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e2" e2="DDI-PubMed.28403576.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e2" e2="DDI-PubMed.28403576.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e3" e2="DDI-PubMed.28403576.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28403576.s6.e3" e2="DDI-PubMed.28403576.s6.e4" /></sentence><sentence text="5 mg and prasugrel 10 mg orally once daily on days 9 to 28"><entity charOffset="9-18" id="DDI-PubMed.28403576.s7.e0" text="prasugrel" /></sentence><sentence text=" In sequence 2, 18 subjects received vorapaxar 40 mg on day 1 and then vorapaxar 2"><entity charOffset="37-46" id="DDI-PubMed.28403576.s8.e0" text="vorapaxar" /><entity charOffset="71-80" id="DDI-PubMed.28403576.s8.e1" text="vorapaxar" /><pair ddi="false" e1="DDI-PubMed.28403576.s8.e0" e2="DDI-PubMed.28403576.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28403576.s8.e0" e2="DDI-PubMed.28403576.s8.e1" /></sentence><sentence text="5 mg once daily on days 2 to 21" /><sentence text=" The geometric mean ratios (90% confidence intervals) for AUCτ and Cmax of coadministration/monotherapy for vorapaxar (0"><entity charOffset="108-117" id="DDI-PubMed.28403576.s10.e0" text="vorapaxar" /></sentence><sentence text="93 ng·h/mL[0" /><sentence text="85-1" /><sentence text="02 ng·h/mL] and 0" /><sentence text="95 ng/mL [0" /><sentence text="86-1" /><sentence text="05 ng/mL]) and R-138727 (0" /><sentence text="91 ng·h/mL [0" /><sentence text="85- 0" /><sentence text="99 ng·h/mL] and 1" /><sentence text="02 ng/mL [0" /><sentence text="89-1" /><sentence text="17 ng/mL]) were within prespecified bounds, demonstrating the absence of a pharmacokinetic interaction between vorapaxar and prasugrel"><entity charOffset="111-120" id="DDI-PubMed.28403576.s22.e0" text="vorapaxar" /><entity charOffset="125-134" id="DDI-PubMed.28403576.s22.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.28403576.s22.e0" e2="DDI-PubMed.28403576.s22.e0" /><pair ddi="false" e1="DDI-PubMed.28403576.s22.e0" e2="DDI-PubMed.28403576.s22.e1" /></sentence><sentence text=" There was no specific safety or tolerability risk associated with multiple-dose coadministration of vorapaxar and prasugrel"><entity charOffset="101-110" id="DDI-PubMed.28403576.s23.e0" text="vorapaxar" /><entity charOffset="115-124" id="DDI-PubMed.28403576.s23.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.28403576.s23.e0" e2="DDI-PubMed.28403576.s23.e0" /><pair ddi="false" e1="DDI-PubMed.28403576.s23.e0" e2="DDI-PubMed.28403576.s23.e1" /></sentence><sentence text=" In conclusion, in this study in healthy volunteers, there was no pharmacokinetic drug-drug interaction between vorapaxar and prasugrel"><entity charOffset="112-121" id="DDI-PubMed.28403576.s24.e0" text="vorapaxar" /><entity charOffset="126-135" id="DDI-PubMed.28403576.s24.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.28403576.s24.e0" e2="DDI-PubMed.28403576.s24.e0" /><pair ddi="false" e1="DDI-PubMed.28403576.s24.e0" e2="DDI-PubMed.28403576.s24.e1" /></sentence><sentence text=" Multiple-dose coadministration of the 2 drugs was generally well tolerated" /><sentence text="" /></document>